---
figid: PMC6587703__fonc-09-00490-g0002
figlink: /pmc/articles/PMC6587703/figure/F2/
number: Figure 2
caption: Mechanistic interactions between VEGF-targeted anti-angiogenic therapy and
  checkpoint inhibitors in the systemic treatment of mRCC. Various VEGF-targeted and
  mTOR-targeted anti-angiogenic agents are currently approved in mRCC, inhibiting
  VEGF-A (bevacizumab); VEGFR1-3, FGFR1-4, PDGFR- α, c-kit, and RET-oncogene (lenvatinib);
  c-MET, AXL and RET, and VEGFR2 (cabozantinib); c-KIT, FGFR, PDGFR, and VEGFR (pazopanib);
  VEGFR1-3, c-KIT, and PDGFR (axitinib); VEGFR, PDGFR, and Raf family kinases (sorafenib);
  VEGFRs, PDGFRs, and RET (sunitinib). Everolimus and temsirolimus are specific inhibitors
  of mTOR and interfere with the synthesis of proteins that regulate proliferation,
  growth and survival of tumor cells. These agents are more selective for the mTORC1
  protein complex, with very little impact on the mTORC2 complex. Nevertheless, increased
  tumor hypoxia during this anti-angiogenic therapy is the key player for developing
  TKI resistance, with consecutive HIF-α accumulation. Under hypoxia, PD-L1 upregulation
  was dependent on HIF-2α in RCC, being associated with simultaneous VEGF overexpression.
  Moreover, specimens from patients treated with anti-angiogenic therapy were associated
  with enhanced expression of PD-L1 (). Thus, combined blockade of PD-L1 (avelumab
  or atezolizumab) or PD-1 (nivolumab or pembrolizumab) along with inhibition of the
  angiogenesis pathway is an innovative therapeutic concept in mRCC.
pmcid: PMC6587703
papertitle: Targeting the Tumor Microenvironment in Renal Cell Cancer Biology and
  Therapy.
reftext: Isabel Heidegger, et al. Front Oncol. 2019;9:490.
pmc_ranked_result_index: '97180'
pathway_score: 0.9439204
filename: fonc-09-00490-g0002.jpg
figtitle: Mechanistic interactions between VEGF-targeted anti-angiogenic therapy and
  checkpoint inhibitors in the systemic treatment of mRCC
year: '2019'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6587703__fonc-09-00490-g0002.html
  '@type': Dataset
  description: Mechanistic interactions between VEGF-targeted anti-angiogenic therapy
    and checkpoint inhibitors in the systemic treatment of mRCC. Various VEGF-targeted
    and mTOR-targeted anti-angiogenic agents are currently approved in mRCC, inhibiting
    VEGF-A (bevacizumab); VEGFR1-3, FGFR1-4, PDGFR- α, c-kit, and RET-oncogene (lenvatinib);
    c-MET, AXL and RET, and VEGFR2 (cabozantinib); c-KIT, FGFR, PDGFR, and VEGFR (pazopanib);
    VEGFR1-3, c-KIT, and PDGFR (axitinib); VEGFR, PDGFR, and Raf family kinases (sorafenib);
    VEGFRs, PDGFRs, and RET (sunitinib). Everolimus and temsirolimus are specific
    inhibitors of mTOR and interfere with the synthesis of proteins that regulate
    proliferation, growth and survival of tumor cells. These agents are more selective
    for the mTORC1 protein complex, with very little impact on the mTORC2 complex.
    Nevertheless, increased tumor hypoxia during this anti-angiogenic therapy is the
    key player for developing TKI resistance, with consecutive HIF-α accumulation.
    Under hypoxia, PD-L1 upregulation was dependent on HIF-2α in RCC, being associated
    with simultaneous VEGF overexpression. Moreover, specimens from patients treated
    with anti-angiogenic therapy were associated with enhanced expression of PD-L1
    (). Thus, combined blockade of PD-L1 (avelumab or atezolizumab) or PD-1 (nivolumab
    or pembrolizumab) along with inhibition of the angiogenesis pathway is an innovative
    therapeutic concept in mRCC.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FGF22
  - FGF21
  - FGF23
  - ACTC1
  - ACTG2
  - ACTB
  - AKT1
  - ACTG1
  - CD28
  - AKT3
  - FGF13
  - AKT2
  - FGF20
  - ACTA2
  - MAPK3
  - MAPK1
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FGF1
  - FGF11
  - FGF12
  - FGF14
  - ACTA1
  - PDGFD
  - PDGFRA
  - PDGFRB
  - CD274
  - PTEN
  - FGF18
  - FGF17
  - FGF16
  - FGF19
  - FGF10
  - FGF2
  - PDGFA
  - PDGFB
  - SOS2
  - TGFA
  - VEGFD
  - PGF
  - VEGFA
  - VEGFB
  - VEGFC
  - FLT1
  - FLT4
  - KDR
  - CDC42
  - MET
  - MYC
  - CTLA4
  - CCND1
  - EPAS1
  - HIF1A
  - HIF3A
  - MTOR
  - RICTOR
  - MLST8
  - MAPKAP1
  - PDCD1
  - PDGFC
  - NRAS
  - FGF3
  - FGF4
  - FGFR4
  - FGFRL1
  - FGFR3
  - FGFR1
  - ARAF
  - RAF1
  - BRAF
  - RPTOR
  - HRAS
  - KRAS
  - ARNT
  - ARNTL
  - ARNT2
  - GAB1
  - GRB2
  - GAL
  - FGFR2
  - VHL
  - SOS1
  - Lenvatinib
  - Caborantinib
  - Pazopanib
  - Axitinib
  - Everolimu
  - TCR
  - VHL tumor
  - Hypoxia
  - VHL
genes:
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF22
  entrez: '27006'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF21
  entrez: '26291'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF23
  entrez: '8074'
- word: actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTC1
  entrez: '70'
- word: actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTG2
  entrez: '72'
- word: actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTB
  entrez: '60'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTG1
  entrez: '71'
- word: CD28
  symbol: CD28
  source: hgnc_symbol
  hgnc_symbol: CD28
  entrez: '940'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF13
  entrez: '2258'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF20
  entrez: '26281'
- word: actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTA2
  entrez: '59'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF5
  entrez: '2250'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF6
  entrez: '2251'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF7
  entrez: '2252'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF8
  entrez: '2253'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF9
  entrez: '2254'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF1
  entrez: '2246'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF11
  entrez: '2256'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF12
  entrez: '2257'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF14
  entrez: '2259'
- word: actin
  symbol: Actin
  source: bioentities_symbol
  hgnc_symbol: ACTA1
  entrez: '58'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFD
  entrez: '80310'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRA
  entrez: '5156'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: PD-L1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF18
  entrez: '8817'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF17
  entrez: '8822'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF16
  entrez: '8823'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF19
  entrez: '9965'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF10
  entrez: '2255'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF2
  entrez: '2247'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFA
  entrez: '5154'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFB
  entrez: '5155'
- word: sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS2
  entrez: '6655'
- word: TGF-a
  symbol: TGFA
  source: hgnc_symbol
  hgnc_symbol: TGFA
  entrez: '7039'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: CDC42
  symbol: CDC42
  source: hgnc_symbol
  hgnc_symbol: CDC42
  entrez: '998'
- word: C-MET
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: c-Myc
  symbol: c-Myc
  source: hgnc_alias_symbol
  hgnc_symbol: MYC
  entrez: '4609'
- word: CTLA-4
  symbol: CTLA4
  source: hgnc_symbol
  hgnc_symbol: CTLA4
  entrez: '1493'
- word: CyclinD1
  symbol: Cyclin-D1
  source: bioentities_symbol
  hgnc_symbol: CCND1
  entrez: '595'
- word: HIF2a
  symbol: HIF2A
  source: hgnc_alias_symbol
  hgnc_symbol: EPAS1
  entrez: '2034'
- word: HIFa
  symbol: HIF_alpha
  source: bioentities_symbol
  hgnc_symbol: EPAS1
  entrez: '2034'
- word: HIFa
  symbol: HIF_alpha
  source: bioentities_symbol
  hgnc_symbol: HIF1A
  entrez: '3091'
- word: HIFa
  symbol: HIF_alpha
  source: bioentities_symbol
  hgnc_symbol: HIF3A
  entrez: '64344'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: RICTOR
  entrez: '253260'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MLST8
  entrez: '64223'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MAPKAP1
  entrez: '79109'
- word: PD-1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFC
  entrez: '56034'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF3
  entrez: '2248'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF4
  entrez: '2249'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR4
  entrez: '2264'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFRL1
  entrez: '53834'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR3
  entrez: '2261'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR1
  entrez: '2260'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: Raptor
  symbol: raptor
  source: hgnc_alias_symbol
  hgnc_symbol: RPTOR
  entrez: '57521'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: HIF.
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: HIF1A
  entrez: '3091'
- word: HIF.
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNT
  entrez: '405'
- word: HIF.
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNTL
  entrez: '406'
- word: HIF.
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNT2
  entrez: '9915'
- word: GAB1/GRB2
  symbol: GAB1
  source: hgnc_symbol
  hgnc_symbol: GAB1
  entrez: '2549'
- word: GAB1/GRB2
  symbol: GRB2
  source: hgnc_symbol
  hgnc_symbol: GRB2
  entrez: '2885'
- word: GAL
  symbol: GAL
  source: hgnc_symbol
  hgnc_symbol: GAL
  entrez: '51083'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR2
  entrez: '2263'
- word: HIF.
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: EPAS1
  entrez: '2034'
- word: VHL
  symbol: VHL
  source: hgnc_symbol
  hgnc_symbol: VHL
  entrez: '7428'
- word: HIF.
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: HIF3A
  entrez: '64344'
- word: sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS1
  entrez: '6654'
- word: Rictor
  symbol: RICTOR
  source: hgnc_symbol
  hgnc_symbol: RICTOR
  entrez: '253260'
chemicals:
- word: Lenvatinib
  source: MESH
  identifier: C531958
- word: Caborantinib
  source: ''
  identifier: ''
- word: Pazopanib
  source: MESH
  identifier: C516667
- word: Axitinib
  source: MESH
  identifier: C503983
- word: Everolimu
  source: ''
  identifier: ''
- word: TCR
  source: MESH
  identifier: D017260
diseases:
- word: VHL tumor
  source: MESH
  identifier: D006623
- word: Hypoxia
  source: MESH
  identifier: D000860
- word: VHL
  source: MESH
  identifier: D006623
---
